UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037771
Receipt number R000043070
Scientific Title Development of neo-self antibody research for recurrent pregnancy loss and obstetric complications
Date of disclosure of the study information 2019/08/22
Last modified on 2021/11/04 09:03:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Development of neo-self antibody research for recurrent pregnancy loss and obstetric complications

Acronym

Development of neo-self antibody research for recurrent pregnancy loss and obstetric complications

Scientific Title

Development of neo-self antibody research for recurrent pregnancy loss and obstetric complications

Scientific Title:Acronym

Development of neo-self antibody research for recurrent pregnancy loss and obstetric complications

Region

Japan


Condition

Condition

Recurrent pregnancy loss, obstetric complications, sterility

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of association between beta2GPI/HLA-DR7 antibody and recurrent pregnancy loss, obstetric complications, and sterility. Development of measurement and therapy methods.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase I,II


Assessment

Primary outcomes

A caste-control study evaluate whether beta2GPI/HLA-DR7 antibody is associated with recurrent pregnancy loss, obstetric complications, or sterility

Key secondary outcomes

A cohort study for pregnant women (<21GW) evaluate whether beta2GPI/HLA-DR7 antibody is associated with obstetric complications


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

45 years-old >=

Gender

Female

Key inclusion criteria

1) Recurrent pregnancy loss
2) FGR
3) HDP
4) Preterm delivery
5) Sterility
6) Normal delivery without 1)-4)
7) Autoimmune disease
obtaining written informed consent in 1)-7)

Key exclusion criteria

1) Less than 18 years, or more than 45 years old
2) Inappropriate subjects
3) Multiple pregnancy or pregnancy with fetal anomaly

Target sample size

1200


Research contact person

Name of lead principal investigator

1st name Hideto
Middle name
Last name Yamada

Organization

Kobe University Graduate School of Medicine

Division name

Department of Obstetrics & Gynecology

Zip code

650-0017

Address

7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan

TEL

0783826000

Email

yhideto@med.kobe-u.ac.jp


Public contact

Name of contact person

1st name Kenji
Middle name
Last name Tanimura

Organization

Kobe University Graduate School of Medicine

Division name

Department of Obstetrics & Gynecology

Zip code

650-0017

Address

7-5-1 Kusunoki-cho Chuo-ku, Kobe, Japan

TEL

0783826000

Homepage URL


Email

taniken@med.kobe-u.ac.jp


Sponsor or person

Institute

Kobe University Graduate School of Medicine
Department of Obstetrics & Gynecology

Institute

Department

Personal name



Funding Source

Organization

AMED

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kobe University Hospital Clinical Translational Research Center

Address

7-5-2 Kusunoki-cho Chuo-ku, Kobe, Japan

Tel

078-382-6669

Email

kansatsu@med.kobe-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions


Other administrative information

Date of disclosure of the study information

2019 Year 08 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2019 Year 07 Month 16 Day

Date of IRB

2019 Year 07 Month 16 Day

Anticipated trial start date

2019 Year 08 Month 01 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The study is in progress.


Management information

Registered date

2019 Year 08 Month 22 Day

Last modified on

2021 Year 11 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043070


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name